Label: P-CARE 100MX- bupivacaine hydrochloride, lidocaine hydrochloride, sodium chloride, povidone-iodine, isopropyl alcohol kit

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated January 31, 2020

If you are a consumer or patient please visit this version.

  • Marcaine - bupivacaine hydrochloride injection, solution

    MarcaineTM
    Bupivacaine Hydrochloride Injection, USP

    MarcaineTM
    With Epinephrine 1:200,000 (as bitartrate) Bupivacaine Hydrochloride and Epinephrine Injection, USP

    Hospira, Inc.

    Rx only

  • DESCRIPTION

    Bupivacaine hydrochloride is 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-,monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula:

    Marcaine Structural Formula

    Marcaine Structural Formula

    Epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl] benzyl alcohol. It has the following structural formula:

    Epinephrine Structural Formula

    Epinephrine Structural Formula

    MARCAINE is available in sterile isotonic solutions with and without epinephrine (as bitartrate) 1:200,000 for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Solutions of MARCAINE may be autoclaved if they do not contain epinephrine. Solutions are clear and colorless.

    Bupivacaine is related chemically and pharmacologically to the aminoacyl local anesthetics. It is a homologue of mepivacaine and is chemically related to lidocaine. All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino, or piperidine group. They differ in this respect from the procaine-type local anesthetics, which have an ester linkage.

    MARCAINE—Sterile isotonic solutions containing sodium chloride. In multiple-dose vials, each mL also contains 1 mg methylparaben as antiseptic preservative. The pH of these solutions is adjusted to between 4 and 6.5 with sodium hydroxide or hydrochloric acid.

    MARCAINEwith epinephrine 1:200,000 (as bitartrate)—Sterile isotonic solutions containing sodium chloride. Each mL contains bupivacaine hydrochloride and 0.0091 mg epinephrine bitartrate, with 0.5 mg sodium metabisulfite, 0.001 mL monothioglycerol, and 2 mg ascorbic acid as antioxidants, 0.0017 mL 60% sodium lactate buffer, and 0.1 mg edetate calcium disodium as stabilizer. In multiple-dose vials, each mL also contains 1 mg methylparaben as antiseptic preservative. The pH of these solutions is adjusted to between 3.4 and 4.5 with sodium hydroxide or hydrochloric acid. The specific gravity of MARCAINE 0.5% with epinephrine 1:200,000 (as bitartrate) at 25°C is 1.008 and at 37°C is 1.008.

  • CLINICAL PHARMACOLOGY

    Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

    Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems (CNS). At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Recent clinical reports and animal research suggest that  these cardiovascular changes are more likely to occur after unintended
    intravascular injection of bupivacaine. Therefore, incremental dosing is necessary.

    Following systemic absorption, local anesthetics can produce CNS stimulation, depression, or both. Apparent central stimulation is manifested as restlessness, tremors and shivering progressing to convulsions, followed by depression and coma progressing ultimately to respiratory arrest. However,
    the local anesthetics have a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited state.

    Pharmacokinetics: The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution. A dilute concentration of epinephrine (1:200,000 or 5 mcg/mL) usually reduces the rate of absorption and peak plasma concentration of MARCAINE, permitting the use of moderately larger total doses and sometimes prolonging the duration of action.

    The onset of action with MARCAINE is rapid and anesthesia is long lasting. The duration of anesthesia is significantly longer with MARCAINE than with any other commonly used local anesthetic. It has also been noted that there is a period of analgesia that persists after the return of sensation, during which time the need for strong analgesics is reduced.

    The onset of action following dental injections is usually 2 to 10 minutes and anesthesia may last two or three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000.

    Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug the higher the percentage of drug bound to plasma proteins.

    Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by (1) the degree of plasma protein binding, (2) the degree of ionization, and (3) the degree of lipid solubility. Fetal/ maternal ratios of local anesthetics appear to be inversely related to the degree of
    plasma protein binding, because only the free, unbound drug is available for placental transfer.


    MARCAINE with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4). The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation.

    Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.

    Pharmacokinetic studies on the plasma profile of MARCAINE after direct intravenous injection suggest a three-compartment open model. The first compartment is represented by the rapid intravascular distribution of the drug. The second compartment represents the equilibration of the drug throughout
    the highly perfused organs such as the brain, myocardium, lungs, kidneys, and liver. The third compartment represents an equilibration of the drug with poorly perfused tissues, such as muscle and fat. The elimination of drug from tissue distribution depends largely upon the ability of binding sites in the circulation to carry it to the liver where it is metabolized.

    After injection of MARCAINE for caudal, epidural, or peripheral nerve block in man, peak levels of bupivacaine in the blood are reached in 30 to 45 minutes, followed by a decline to insignificant levels during the next three to six hours.

    Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient. The half-life of MARCAINE in adults is 2.7 hours and in neonates 8.1 hours.

    In clinical studies, elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger patients. Elderly patients also exhibited higher peak plasma concentrations following administration of this product. The total plasma clearance was decreased in these patients.

    Amide-type local anesthetics such as MARCAINE are metabolized primarily in the liver via conjugation with glucuronic acid. Patients with hepatic disease, especially those with severe hepatic disease, may be more susceptible to the potential toxicities of the amide-type local anesthetics. Pipecoloxylidine is the major metabolite of MARCAINE.

    The kidney is the main excretory organ for most local anesthetics and their metabolites. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH. Only 6% of bupivacaine is excreted unchanged in the urine.

    When administered in recommended doses and concentrations, MARCAINE does not ordinarily produce irritation or tissue damage.

  • INDICATIONS AND USAGE

    MARCAINE is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS.)

    Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of MARCAINE in these patients.

    MARCAINE is not recommended for intravenous regional anesthesia (Bier Block). See WARNINGS. The routes of administration and indicated MARCAINE concentrations are:

    • local infiltration
    0.25% 
    • peripheral nerve block
    0.25%, and 0.5% 
    • retrobulbar block
    0.75% 
    • sympathetic block
    0.25% 
    • lumbar epidural

    0.25%, 0.5%, and 0.75%

    (0.75% not for obstetrical anesthesia)


    • caudal
    0.25% and 0.5%
    • epidural test dose
    0.5% with epinephrine 1:200,000 
    • dental blocks
    0.5% with epinephrine 1:200,000  

    (See DOSAGE AND ADMINISTRATION for additional information).

    Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of MARCAINE.

  • CONTRAINDICATIONS

    MARCAINE is contraindicated in obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death.

    MARCAINE is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type or to other components of MARCAINE solutions.

  • WARNINGS

    THE 0.75% CONCENTRATION OF MARCAINE IS NOT RECOMMENDED FOR OBSTETRICAL ANESTHESIA. THERE HAVE BEEN REPORTS OF CARDIAC ARREST WITH DIFFICULT RESUSCITATION OR DEATH DURING USE OF MARCAINE FOR EPIDURAL ANESTHESIA IN OBSTETRICAL PATIENTS. IN MOST CASES, THIS HAS FOLLOWED USE OF THE 0.75% CONCENTRATION. RESUSCITATION HAS BEEN DIFFICULT OR IMPOSSIBLE DESPITE APPARENTLY ADEQUATE PREPARATION AND APPROPRIATE MANAGEMENT. CARDIAC ARREST HAS OCCURRED AFTER CONVULSIONS RESULTING FROM SYSTEMIC TOXICITY, PRESUMABLY FOLLOWING UNINTENTIONAL INTRAVASCULAR INJECTION. THE 0.75% CONCENTRATION SHOULD BE RESERVED FOR SURGICAL PROCEDURES WHERE A HIGH DEGREE OFMUSCLE RELAXATION AND PROLONGED EFFECT ARE NECESSARY.

    LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT, AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES. (See also
    ADVERSE REACTIONS, PRECAUTIONS, and OVERDOSAGE.) DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE, AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.

    Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

    Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious CNS and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue MARCAINE and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

    Local anesthetic solutions containing antimicrobial preservatives, i.e., those supplied in multiple-dose vials, should not be used for epidural or caudal anesthesia because safety has not been established with regard to intrathecal injection, either intentionally or unintentionally, of such preservatives.

    Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.

    It is essential that aspiration for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection.

    MARCAINE with epinephrine 1:200,000 or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. Likewise, solutions of MARCAINE containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamineoxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result.

    Until further experience is gained in pediatric patients younger than 12 years, administration of MARCAINE in this age group is not recommended.

    Mixing or the prior or intercurrent use of any other local anesthetic with MARCAINE cannot be recommended because of insufficient data on the clinical use of such mixtures.

    There have been reports of cardiac arrest and death during the use of MARCAINE for intravenous regional anesthesia (Bier Block). Information on safe dosages and techniques of administration of MARCAINE in this procedure is lacking. Therefore, MARCAINE is not recommended for use in this technique.

    MARCAINE with epinephrine 1:200,000 contains sodium metabisulfite, a sulfite that may cause allergic- type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Single-dose ampuls and single-dose vials of MARCAINE without epinephrine do not contain sodium metabisulfite.

  • PRECAUTIONS

    General: The safety and effectiveness of local anesthetics depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (See WARNINGS, ADVERSE REACTIONS, and OVERDOSAGE). During major regional nerve blocks, the patient should have intravenous fluids running via an indwelling catheter to assure a functioning intravenous pathway. The lowest dosage of local anesthetic that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should be used when feasible.

    Epidural Anesthesia: During epidural administration of MARCAINE, 0.5% and 0.75% solutions should be administered in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. Injections should be made slowly, with frequent aspirations before and during the injection to avoid intravascular injection. Syringe aspirations should also be performed before and during each
    supplemental injection in continuous (intermittent) catheter techniques. An intravascular injection is still possible even if aspirations for blood are negative.

    During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and the effects monitored before the full dose is given. When using a "continuous" catheter technique, test doses should be given prior to both the original and all reinforcing doses, because plastic tubing in the epidural space can migrate into a blood vessel or through the dura. When clinical conditions permit, the test dose should contain epinephrine (10 mcg to 15 mcg has been suggested) to serve as a warning of unintended intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient "epinephrine response" within 45 seconds, consisting of an increase in heart rate and/or systolic blood pressure, circumoral pallor, palpitations, and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Therefore, following the test dose, the heart rate should be monitored for a heart rate increase. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a transient rise in systolic blood pressure. The test dose should also contain 10 mg to 15
    mg of MARCAINE or an equivalent amount of another local anesthetic to detect an unintended intrathecal administration. This will be evidenced within a few minutes by signs of spinal block (e.g., decreased sensation of the buttocks, paresis of the legs, or, in the sedated patient, absent knee jerk). The Test Dose formulation of MARCAINE contains 15 mg of bupivacaine and 15 mcg of epinephrine in a volume of 3 mL. An intravascular or subarachnoid injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or epinephrine-induced cardiovascular effects.

    Injection of repeated doses of local anesthetics may cause significant increases in plasma levels with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients and acutely ill patients should be given reduced doses commensurate with their age and physical status. Local anesthetics should also be used with caution in patients with hypotension or heartblock.

    Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after each local anesthetic injection. It should be kept in mind at such times that restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, depression, or drowsiness may be early warning signs of CNS toxicity.

    Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, or penis. Patients with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury or necrosis may result.

    Because amide-local anesthetics such as MARCAINE are metabolized by the liver, these drugs, especially repeat doses, should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. Local anesthetics should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.

    Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are employed in patients during or following the administration of potent inhalation anesthetics. In deciding whether to use these products concurrently in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.

    Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. Because it is not known whether amide-type local anesthetics may trigger this reaction and because the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and prompt institution of treatment, including oxygen therapy, indicated supportive measures and dantrolene (Consult dantrolene sodium intravenous package insert before using).

    Use in Head and Neck Area: Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental, and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. The injection procedures require the utmost care. Confusion, convulsions, respiratory depression, and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. They may also be due to puncture of the dural sheath of the optic nerve during retrobulbar block with diffusion of any local anesthetic along the subdural space to the midbrain. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded (See DOSAGE AND ADMINISTRATION).

    Use in Ophthalmic Surgery: Clinicians who perform retrobulbar blocks should be aware that there have been reports of respiratory arrest following local anesthetic injection. Prior to retrobulbar block, as with all other regional procedures, the immediate availability of equipment, drugs, and personnel to manage respiratory arrest or depression, convulsions, and cardiac stimulation or depression should be assured (see also WARNINGS and Use In Head and Neck Area, above). As with other anesthetic procedures, patients should be constantly monitored following ophthalmic blocks for signs of these adverse reactions, which may occur following relatively low total doses.

    A concentration of 0.75% bupivacaine is indicated for retrobulbar block; however, this concentration is not indicated for any other peripheral nerve block, including the facial nerve, and not indicated for local infiltration, including the conjunctiva (see INDICATIONS AND USAGE and PRECAUTIONS, General). Mixing MARCAINE with other local anesthetics is not recommended because of insufficient data on the clinical use of such mixtures.

    When MARCAINE 0.75% is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clinically acceptable external ocular muscle akinesia. Therefore, presence of akinesia rather than anesthesia alone should determine readiness of the patient for surgery.

    Use in Dentistry: Because of the long duration of anesthesia, when MARCAINE 0.5% with epinephrine is used for dental injections, patients should be cautioned about the possibility of inadvertent trauma to tongue, lips, and buccal mucosa and advised not to chew solid foods or test the anesthetized area by
    biting or probing.

    Information for Patients: When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of caudal or epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the package insert of MARCAINE.

    Patients receiving dental injections of MARCAINE should be cautioned not to chew solid foods or test the anesthetized area by biting or probing until anesthesia has worn off (up to 7 hours).

    Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

    Clinically Significant Drug Interactions: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

    Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
    Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics:

    Examples of Drugs Associated with Methemoglobinemia:

    ClassExamples 
    Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous
    oxide
    Local Anesthetics articaine, benzocaine, bupivacaine, lidocaine,
    mepivacaine, prilocaine, procaine, ropivacaine,
    tetracaine 
    Antineoplastic
    agents 
    cyclophosphamide, flutamide, hydroxyurea,
    isofamide, rasburicase 
    Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid,
    sulfonamides 
    Antimalarials chloroquine, primaquine 
    Anticonvulsants phenobarbital, phenytoin, sodium valproate 
    Other drugs acetaminophen, metoclopramide, quinine,
    sulfasalazine 

    Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate the carcinogenic potential of bupivacaine hydrochloride have not been conducted. The mutagenic potential and the effect on fertility of bupivacaine hydrochloride have not been determined.

    Pregnancy: There are no adequate and well-controlled studies in pregnant women. MARCAINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Bupivacaine hydrochloride produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses. This does not exclude the use of MARCAINE at term for obstetrical anesthesia or analgesia (See Labor and Delivery).

    Bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, & 40 mg/kg and to rabbits at doses of 1.3, 5.8, & 22.2 mg/kg during the period of organogenesis (implantation to closure of the hard palate). The high doses are comparable to the daily maximum recommended
    human dose (MRHD) of 400 mg/day on a mg/m2 body surface area (BSA) basis. No embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality. An increase in embryo-fetal deaths was observed in rabbits at the high dose in the absence of maternal toxicity
    with the fetal No Observed Adverse Effect Level representing approximately 1/5th the MRHD on a BSA basis.

    In a rat pre- and post-natal development study (dosing from implantation through weaning) conducted at subcutaneous doses of 4.4, 13.3, & 40 mg/kg, decreased pup survival was observed at the high dose. The high dose is comparable to the daily MRHD of 400 mg/day on a BSA basis.

    Labor and Delivery: SEE BOXED WARNING REGARDING OBSTETRICAL USE OF0.75% MARCAINE.

    MARCAINE is contraindicated for obstetrical paracervical block anesthesia.

    Local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity (See CLINICAL PHARMACOLOGY, Pharmacokinetics ). The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the CNS, peripheral vascular tone, and cardiac function.

    Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient's legs and positioning her on her left side will help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.

    Epidural, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient's reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.

    The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. This has not been reported with bupivacaine.

    It is extremely important to avoid aortocaval compression by the gravid uterus during administration of regional block to parturients. To do this, the patient must be maintained in the left lateral decubitus position or a blanket roll or sandbag may be placed beneath the right hip and gravid uterus displaced to
    the left.

    Nursing Mothers: Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. Because of the potential for serious adverse reactions in nursing infants from bupivacaine, a decision should be made whether to discontinue
    nursing or not administer bupivacaine, taking into account the importance of the drug to the mother.

    Pediatric Use: Until further experience is gained in pediatric patients younger than 12 years, administration of MARCAINE in this age group is not recommended. Continuous infusions of bupivacaine in children have been reported to result in high systemic levels of bupivacaine and seizures; high plasma levels may also be associated with cardiovascular abnormalities (See WARNINGS, PRECAUTIONS, and OVERDOSAGE).

    Geriatric Use: Patients over 65 years, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with MARCAINE (See ADVERSE REACTIONS).

    Elderly patients may require lower doses of MARCAINE (See PRECAUTIONS, Epidural Anesthesia and DOSAGE AND ADMINISTRATION).

    In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients (See CLINICAL PHARMACOLOGY).

    This product is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to
    monitor renal function (See CLINICAL PHARMACOLOGY).

  • ADVERSE REACTIONS

    Reactions to MARCAINE are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.

    The most commonly encountered acute adverse experiences which demand immediate counter-measures are related to the CNS and the cardiovascular system. These adverse experiences are generally dose related and due to high plasma levels which may result from overdosage, rapid absorption from the
    injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional subarachnoid injection of drug  during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) may result in underventilation or apnea ("Total or High Spinal"). Also, hypotension due to loss of sympathetic
    tone and respiratory paralysis or underventilation due to cephalad extension of the motor level of anesthesia may occur. This may lead to secondary cardiac arrest if untreated. Patients over 65 years, particularly those with hypertension, may be at increased risk for experiencing the hypotensive effects of MARCAINE. Factors influencing plasma protein binding, such as acidosis, systemic diseases which alter protein production, or competition of other drugs for protein binding sites, may diminish individual tolerance.

    CNS Reactions: These are characterized by excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, blurred vision, or tremors may occur, possibly proceeding to convulsions. However, excitement may be transient or absent, with depression being the first manifestation of an adverse reaction. This may quickly be followed by drowsiness merging into unconsciousness and respiratory arrest. Other CNS effects may be nausea, vomiting, chills, and constriction of the pupils.

    The incidence of convulsions associated with the use of local anesthetics varies with the procedure used and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to convulsions occurred in approximately 0.1% of local anesthetic administrations.

    Cardiovascular System Reactions: High doses or unintentional intravascular injection may lead to high plasma levels and related depression of the myocardium, decreased cardiac output, heartblock, hypotension, bradycardia, ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, and cardiac arrest (See WARNINGS, PRECAUTIONS, and OVERDOSAGE).

    Allergic: Allergic-type reactions are rare and may occur as a result of sensitivity to the local anestheticor to other formulation ingredients, such as the antimicrobial preservative methylparaben contained in multiple-dose vials or sulfites in epinephrine-containing solutions. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid-like symptomatology (including severe hypotension). Cross sensitivity among members of the amide-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitely established.

    Neurologic: The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.

    In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter or needle may occur. Subsequent adverse effects may depend partially on the amount of drug administered intrathecally and the physiological and physical effects of a dural puncture. A high spinal is characterized by paralysis of the legs, loss of consciousness, respiratory paralysis, and bradycardia.

    Neurologic effects following epidural or caudal anesthesia may include spinal block of varying magnitude (including high or total spinal block); hypotension secondary to spinal block; urinary retention; fecal and urinary incontinence; loss of perineal sensation and sexual function; persistent anesthesia, paresthesia, weakness, paralysis of the lower extremities and loss of sphincter control all of which may have slow, incomplete, or no recovery; headache; backache; septic meningitis; meningismus; slowing of labor; increased incidence of forceps delivery; and cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid.

    Neurologic effects following other procedures or routes of administration may include persistent anesthesia, paresthesia, weakness, paralysis, all of which may have slow, incomplete, or no recovery.

  • OVERDOSAGE

    Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (See ADVERSE REACTIONS, WARNINGS, and PRECAUTIONS).

    Management of Local Anesthetic Emergencies: The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.

    The first step in the management of systemic toxic reactions, as well as underventilation or apnea due to unintentional subarachnoid injection of drug solution, consists of immediate attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask. This may prevent convulsions if they have not already occurred.

    If necessary, use drugs to control the convulsions. A 50 mg to 100 mg bolus intravenous injection of succinylcholine will paralyze the patient without depressing the CNS or cardiovascular systems and facilitate ventilation. A bolus intravenous dose of 5 mg to 10 mg of diazepam or 50 mg to 100 mg of
    thiopental will permit ventilation and counteract CNS stimulation, but these drugs also depress CNS, respiratory, and cardiac function, add to postictal depression and may result in apnea. Intravenous barbiturates, anticonvulsant agents, or muscle relaxants should only be administered by those familiar with their use. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated. Supportive treatment of circulatory depression may require administration of intravenous fluids, and when appropriate, a vasopressor dictated by the clinical situation (such as ephedrine or epinephrine to enhance myocardial contractile force).

    Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated.

    Recent clinical data from patients experiencing local anesthetic-induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis with bupivacaine within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.

    If not treated immediately, convulsions with simultaneous hypoxia, hypercarbia, and acidosis plus myocardial depression from the direct effects of the local anesthetic may result in cardiac arrhythmias, bradycardia, asystole, ventricular fibrillation, or cardiac arrest. Respiratory abnormalities, including apnea, may occur. Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to
    cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, successful outcome may require prolonged resuscitative efforts.

    The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. Therefore during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible, or manual displacement of the uterus off the great vessels be accomplished.

    The mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. The intravenous and subcutaneous LD50 in mice is 6 mg/kg to 8 mg/kg and 38 mg/kg to 54 mg/kg respectively.

  • DOSAGE AND ADMINISTRATION

    The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of MARCAINE should be reduced for elderly and/or debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should be used when feasible.

    For specific techniques and procedures, refer to standard textbooks.

    There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. MARCAINE is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).

    In recommended doses, MARCAINE produces complete sensory block, but the effect on motor function differs among the three concentrations.

    0.25%—when used for caudal, epidural, or peripheral nerve block, produces incomplete motor block. Should be used for operations in which muscle relaxation is not important, or when another means of providing muscle relaxation is used concurrently. Onset of action may be slower than with the 0.5% or 0.75% solutions.

    0.5%— provides motor blockade for caudal, epidural, or nerve block, but muscle relaxation may be inadequate for operations in which complete muscle relaxation is essential.

    0.75%—produces complete motor block. Most useful for epidural block in abdominal operations requiring complete muscle relaxation, and for retrobulbar anesthesia. Not for obstetrical anesthesia.

    The duration of anesthesia with MARCAINE is such that for most indications, a single-dose is sufficient.

    Maximum dosage limit must be individualized in each case after evaluating the size and physical status of the patient, as well as the usual rate of systemic absorption from a particular injection site. Most experience to date is with single-doses of MARCAINE up to 225 mg with epinephrine 1:200,000 and 175 mg without epinephrine; more or less drug may be used depending on individualization of each case.

    These doses may be repeated up to once every three hours. In clinical studies to date, total daily doses have been up to 400 mg. Until further experience is gained, this dose should not be exceeded in 24 hours. The duration of anesthetic effect may be prolonged by the addition of epinephrine.

    The dosages in Table 1 have generally proved satisfactory and are recommended as a guide for use in the average adult. These dosages should be reduced for elderly or debilitated patients. Until further experience is gained, MARCAINE is not recommended for pediatric patients younger than 12 years. MARCAINE is contraindicated for obstetrical paracervical blocks, and is not recommended for intravenous regional anesthesia (Bier Block).

    Use in Epidural Anesthesia: During epidural administration of MARCAINE, 0.5% and 0.75% solutions should be administered in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. In obstetrics, only the 0.5% and 0.25% concentrations should be used; incremental doses of 3 mL to 5 mL of the 0.5% solution not exceeding 50 mg to 100 mg at any dosing interval are recommended. Repeat doses should be preceded by a test dose containing epinephrine if not contraindicated. Use only the single-dose ampuls and single-dose vials for caudal or epidural anesthesia; the multiple-dose vials contain a preservative and therefore should not be used for these procedures.

    Test Dose for Caudal and Lumbar Epidural Blocks: The Test Dose of MARCAINE (0.5% bupivacaine with 1:200,000 epinephrine in a 3 mL ampul) is recommended for use as a test dose when clinical conditions permit prior to caudal and lumbar epidural blocks. This may serve as a warning of unintended intravascular or subarachnoid injection (See PRECAUTIONS). The pulse rate and other signs should be monitored carefully immediately following each test dose administration to detect possible intravascular injection, and adequate time for onset of spinal block should be allotted to detect possible intrathecal injection. An intravascular or subarachnoid injection is still possible even if results of the  test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or cardiovascular effects from the epinephrine (See WARNINGS and OVERDOSAGE).

    Unused portions of solution not containing preservatives, i.e., those supplied in single-dose ampuls and single-dose vials, should be discarded following initial use.

    This product should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Solutions which are discolored or which contain particulate matter should not be administered.

    Table 1. Recommended Concentrations and Doses of MARCAINE

    Type of Block Conc. Each dose ((mL) Each Dose (mg) Motor Block 1 
    Local Infiltration 0.25%4 up to max.up to max. ----------
    Epidural 

    0.75%2,4

    10-20

    75-100

    complete

     0.5%4 10-20 50-100 moderate to complete 
     0.25410-2025-50partial to moderate 
    Caudal0.5%4 15-3075-150 moderate to complete 
     0.25%4 15-30 37.5-75 moderate 
    Peripheral nerves 0.5%4 5 to max. 25 to max. moderate to complete 
     0.25%4 5 to max. 12.5 to max. moderate to complete 
    Retrobulbar3 0.75%4 2-4 15-30 complete 
    Sympathetic 0.25% 20-50 50-125 ----------- 
    Dental3 0.5% 1.8-3.6 9-18 ----------- 
     w/epi per site per site ----------- 
    Epidural3 0.5% 2-3 10-15 ----------- 
    Test Dose w/epi  (10-15 micrograms epinephrine) 

    1With continuous (intermittent) techniques, repeat doses increase the degree of motor block. The first repeat dose of 0.5% may produce complete motor block. Intercostal nerve block with 0.25% may also produce complete motor block for intra-abdominal surgery.

    2 For single-dose use, not for intermittent epidural technique. Not for obstetrical anesthesia.

    3 See PRECAUTIONS.

    4 Solutions with or without epinephrine.

  • HOW SUPPLIED

    These solutions are not for spinal anesthesia.

    Store at 20 to 25°C (68 to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]

    MARCAINE―Solutions of MARCAINE that do not contain epinephrine may be autoclaved. Autoclave at 15-pound pressure, 121°C (250°F) for 15 minutes.

    Unit of Sale Concentration Each 
      0.25% Contains 2.5 mg bupivacaine hydrochloride per mL. 
    NDC 0409-1559-10
    Tray of 10 

    25 mg/10 mL
    (2.5 mg/mL)

    NDC 0409-1559-18
    Single-dose vial
    NDC 0409-1559-30
    Carton of 10
    75 mg/30 mL
    (2.5 mg/mL)

    NDC 0409-1559-19
    Single-dose vial

    NDC 0409-1587-50
    Carton of 1 
    125 mg/50 mL
    (2.5 mg/mL)
    NDC 0409-1587-50
    Multiple-dose vial
     0.5% Contains 5 mg bupivacaine hydrochloride per mL.  
    NDC 0409-1560-10
    Tray of 10 
    50 mg/10 mL
    (5 mg/mL) 
    NDC 0409-1560-18
    Single-dose vial 
    NDC 0409-1560-29
    Carton of 10 
    150 mg/30 mL
    (5 mg/mL)
    NDC 0409-1560-19
    Single-dose vial 
    NDC 0409-1610-50
    Carton of 1
    250 mg/50 mL
    (5 mg/mL) 
    NDC 0409-1610-50
    Multiple-dose vial 
     0.75% Contains 7.5 mg bupivacaine hydrochloride per mL.  
    NDC 0409-1582-10
    Tray of 10
    75 mg/10 mL
    (7.5 mg/mL) 
    NDC 0409-1582-18
    Single-dose vial 
    NDC 0409-1582-29
    Carton of 10 
    225 mg/30 mL
    (7.5 mg/mL) 
    NDC 0409-1582-19
    Single-dose vial 

    MARCAINE with epinephrine 1:200,000 (as bitartrate)―Solutions of MARCAINE that contain epinephrine should not be autoclaved and should be protected from light. Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate.

    Unit of SaleConcentrationEach 
     

    0.25% with epinephrine 1:200,000

    Contains 2.5 mg bupivacaine hydrochloride per mL.

     

    NDC 0409-1746-10

    Carton of 10 

     25 mg/10 mL

    (2.5 mg/mL)

    NDC 0409-1746-70

    Single-dose vial

    NDC 0409-1746-30

    Carton of 10 

     75 mg/30 mL

    (2.5 mg/mL)

    NDC 0409-1746-71

    Single-dose vial

    NDC 0409-1752-50

    Carton of 1

     125 mg/50 mL

    (2.5 mg/mL)

    NDC 0409-1752-50

    Multiple-dose vial

     

    0.5% with epinephrine 1:200,000

    Contains 5 mg bupivacaine hydrochloride per mL. 

     

    NDC 0409-1749-10

    Carton of 10

     50 mg/10 mL

    (5 mg/mL)

    NDC 0409-1749-70

    Single-dose vial

    NDC 0409-1749-29

    Carton of 10

     150 mg/30 mL

    (5 mg/mL)

    NDC 0409-1749-71

    Single-dose vial

    NDC 0409-1755-50

    Carton of 1

    250 mg/50 mL

    (5 mg/mL) 

    NDC 0409-1755-50

    Multiple-dose vial

    For single-dose vials: Discard unused portion.

    Distributed by Hospira , Inc.,

    Lake Forest , IL 60045

    USA

    Revised: 11/2018

  • XYLOCAINE - lidocaine hydrochloride injection, solution                                  

    XYLOCAINE  MPF- lidocaine hydrochloride injection, solution
    XYLOCAINE - lidocaine hydrochloride injection, solution
    XYLOCAINE  MPF- lidocaine hydrochloride, epinephrine bitartrate injection, solution
    XYLOCAINE - lidocaine hydrochloride, epinephrine bitartrate injection, solution

    Fresenius Kabi USA, LLC

    Xylocaine®
    (lidocaine HCl Injection, USP)

    Xylocaine®
    (lidocaine HCl and epinephrine Injection, USP)

    For Infiltration and Nerve Block

    Rx only

  • DESCRIPTION

    Xylocaine (lidocaine HCl) Injections are sterile, nonpyrogenic, aqueous solutions that contain a local anesthetic agent with or without epinephrine and are administered parenterally by injection. See INDICATIONS AND USAGE for specific uses.

    Xylocaine solutions contain lidocaine HCl, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride and has the molecular wt. 270.8.  Lidocaine HCl (C14H22N2O • HCl) has the following structural formula:

    Xylocaine Structural Formula

    Xylocaine Structural Formula

    Epinephrine is (-) -3, 4-Dihydroxy-α-[(methylamino) methyl] benzyl alcohol and has the molecular wt. 183.21.  Epinephrine (C9H13NO3) has the following structural formula:

    Epinephrine Structural Formula

    Epinephrine Structural Formula


    Dosage forms listed as Xylocaine-MPF indicate single dose solutions that are Methyl Paraben Free (MPF).

    Xylocaine MPF is a sterile, nonpyrogenic, isotonic solution containing sodium chloride. 

    Xylocaine in multiple dose vials:  Each mL also contains 1 mg methylparaben as antiseptic preservative. 

    The pH of these solutions is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and/or hydrochloric acid.

    Xylocaine MPF with Epinephrine is a sterile, nonpyrogenic, isotonic solution containing sodium chloride.  Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer. 

    Xylocaine with Epinephrine in multiple dose vials:  Each mL also contains 1 mg methylparaben as antiseptic preservative. 

    The pH of these solutions is adjusted to approximately 4.5 (3.3 to 5.5) with sodium hydroxide and/or hydrochloric acid.  Filled under nitrogen.

  • CLINICAL PHARMACOLOGY

    Mechanism of Action
    Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.

    Hemodynamics
    Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure.  With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present.  The net effect is normally a modest hypotension when the recommended dosages are not exceeded.

    Pharmacokinetics  and Metabolism
    Information derived from diverse formulations, concentrations and usages reveals that lidocaine HCl is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a
    vasoconstrictor agent.  Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.

    The plasma binding of lidocaine HCl is dependent on drug concentration, and the fraction bound decreases with increasing concentration.  At concentrations of 1 to 4 mcg of free base per mL 60 to 80 percent of lidocaine HCl is protein bound.  Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

    Lidocaine HCl crosses the blood-brain and placental barriers, presumably by passive diffusion.

    Lidocaine HCl is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys.  Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.  N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than,
    those of lidocaine HCl.  Approximately 90% of lidocaine HCl administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged.  The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.

    The elimination half-life of lidocaine HCl following an intravenous bolus injection is typically 1.5 to 2 hours.  Because of the rapid rate at which lidocaine HCl is metabolized, any condition that affects liver function may alter lidocaine HCl kinetics.  The half-life may be prolonged two-fold or more in patients with liver dysfunction.  Renal dysfunction does not affect lidocaine HCl kinetics but may increase the accumulation of metabolites.

    Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine HCl required to produce overt systemic effects.  Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL.  In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity.

  • INDICATIONS AND USAGE

    Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.



  • CONTRAINDICATIONS

    Lidocaine HCl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.



  • WARNINGS

    XYLOCAINE INJECTIONS FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and PRECAUTIONS).  DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY,
    UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.

    Methemoglobinemia
    Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

    Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Xylocaine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

    Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions.  The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours.  There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery.  Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.

    To avoid intravascular injection, aspiration should be performed before the local anesthetic solution is injected.  The needle must be repositioned until no return of blood can be elicited by aspiration.  Note, however, that  the absence of blood in the syringe does not guarantee that intravascular injection has
    been avoided.

    Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental.

    Xylocaine with epinephrine solutions contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

    Anaphylactic reactions may occur following administration of lidocaine hydrochloride (see ADVERSE REACTIONS).

    In the case of severe reaction, discontinue the use of the drug.

  • PRECAUTIONS

    General
    The safety and effectiveness of lidocaine HCl depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies.  Standard textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures.

    Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (see WARNINGS and ADVERSE REACTIONS).  The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects.  Syringe aspirations should also be performed before and during each supplemental injection when using indwelling catheter techniques.  During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and that the patient be monitored for central nervous system toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal administration, before proceeding.  When clinical conditions permit, consideration should be given to employing local anesthetic solutions that contain epinephrine for the test dose because circulatory changes compatible with epinephrine may also serve as a warning sign of unintended intravascular injection. An intravascular injection is still possible even if aspirations for blood are negative. Repeated doses of lidocaine HCl may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug or its metabolites.  Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical condition.  Lidocaine HCl should also be used with caution in patients with severe shock or heart block.

    Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: existing neurological disease, spinal deformities, septicemia, and severe hypertension.

    Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully circumscribed quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply.  Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.  Ischemic injury or necrosis may result.  Preparations containing a vasoconstrictor should be used with caution in patients during or following the administration of potent general anesthetic agents, since cardiac arrhythmias may occur under such conditions.

    Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be accomplished after each local anesthetic injection.  It should be kept in mind at such times that restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression or drowsiness may be early warning signs of central nervous system toxicity.

    Since amide-type local anesthetics are metabolized by the liver, Xylocaine Injection should be used with caution in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations.  Xylocaine Injection should also be used with caution in patients with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs.

    Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia.  Since it is not known whether amide-type local anesthetics may trigger this reaction and since the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for the management of malignant hyperthermia should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure and metabolic acidosis may precede temperature elevation.  Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and institution of treatment, including oxygen therapy, indicated supportive measures and dantrolene (consult dantrolene sodium intravenous package insert before using).

    Proper tourniquet technique, as described in publications and standard textbooks, is essential in the performance of intravenous regional anesthesia.  Solutions containing epinephrine or other vasoconstrictors should not be used for this technique.

    Lidocaine HCl should be used with caution in persons with known drug sensitivities.  Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross-sensitivity to lidocaine HCl.

    Use in the Head and Neck Area Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses.  Confusion, convulsions,
    respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported.  These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation.  Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed.  Resuscitative equipment and personnel for treating adverse reactions should be immediately available.  Dosage recommendations should not be exceeded (see DOSAGE AND ADMINISTRATION).

    Information for Patients
    When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia.

    Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

    Clinically Significant Drug Interactions
    The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.

    Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.

    Concurrent use of these agents should generally be avoided.  In situations when concurrent therapy is necessary, careful patient monitoring is essential.

    Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

    Drug/Laboratory Test Interactions
    The intramuscular injection of lidocaine HCl may result in an increase in creatine phosphokinase levels.  Thus, the use of this enzyme determination, without isoenzyme separation, as a diagnostic test for the presence of acute myocardial infarction may be compromised by the intramuscular injection of lidocaine HCl.

    Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:

    Examples of Drugs Associated with Methemoglobinemia:

    Class
    Examples 
    Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide 
    Local anesthetics 

    articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine,

    procaine, ropivacaine, tetracaine 

    Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase 
    Antibiotics dapsone, nitrofurantoin, paraaminosalicylic acid, sulfonamides 
    Antimalarials chloroquine, primaquine 
    Anticonvulsants Phenobarbital, phenytoin, sodium valproate 
    Other drugs
    acetaminophen, metoclopramide, quinine, sulfasalazine 

    Carcinogenesis, Mutagenesis, Impairment of Fertility
    Studies of lidocaine HCl in anima s to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

    Pregnancy

    Teratogenic Effects: Pregnancy Category B.

    Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine HCl. There are, however, no adequate and well-controlled studies in pregnant women.  Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine HCl to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

    Labor and Delivery
    Local anesthetics rapidly cross the placenta and when used for epidural, paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal, fetal and neonatal toxicity (see CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism). The potential for toxicity depends upon the procedure performed, the type and amount of drug used, and the technique of drug administration.  Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function.

    Maternal hypotension has resulted from regional anesthesia.  Local anesthetics produce vasodilation by blocking sympathetic nerves.  Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure.

    The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable.

    Epidural, spinal, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts.  In one study, paracervical block anesthesia was associated with a decrease in the mean duration of first stage labor and facilitation of cervical dilation.  However, spinal and epidural anesthesia have also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function.  The use of obstetrical anesthesia may increase the need for forceps assistance.

    The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life.  The long-term significance of these observations is unknown.  Fetal bradycardia may occur in 20 to 30 percent of patients receiving paracervical nerve block anesthesia with the amide-type local anesthetics and may be associated with fetal acidosis.  Fetal heart rate should always be monitored during paracervical anesthesia.  The physician should weigh the possible advantages against risks when considering a paracervical block in prematurity, toxemia of pregnancy, and fetal distress.  Careful adherence to recommended dosage is of the utmost importance in obstetrical paracervical block.  Failure to achieve adequate analgesia with recommended doses should arouse suspicion of intravascular or fetal intracranial injection.  Cases compatible with unintended fetal intracranial injection of local anesthetic solution have been reported following intended paracervical or pudendal block or both.  Babies so affected present with unexplained neonatal depression at birth, which correlates with high local anesthetic serum levels, and often manifest seizures within six hours.  Prompt use of supportive measures combined with forced urinary excretion of the local anesthetic has been used successfully to manage this complication.

    Case reports of maternal convulsions and cardiovascular collapse following use of some local anesthetics for paracervical block in early pregnancy (as anesthesia for elective abortion) suggest that systemic absorption under these circumstances may be rapid.  The recommended maximum dose of each drug should not be exceeded.  Injection should be made slowly and with frequent aspiration.  Allow a 5-minute interval between sides.

    Nursing Mothers
    It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when lidocaine HCl is administered to a nursing woman.

    Pediatric Use
    Dosages in children should be reduced, commensurate with age, body weight and physical condition (see DOSAGE AND ADMINISTRATION).

  • ADVERSE REACTIONS

    Systemic
    Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents.  These adverse experiences are, in general, dose- related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.  Serious adverse experiences are generally systemic in nature.  The following types are those most commonly reported:

    Central Nervous System

    CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest.  The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.

    Drowsiness following the administration of lidocaine HCl is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

    Cardiovascular System
    Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.

    Allergic
    Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials.  Allergic reactions, including anaphylactic reactions, may occur as a result of sensitivity to lidocaine, but are infrequent.  If allergic reactions do occur, they should be managed by conventional means.  The detection of sensitivity by skin testing is of doubtful value.

    There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine.

    Neurologic
    The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient.  In a prospective review of 10,440 patients who received lidocaine HCl for spinal anesthesia, the incidences of adverse reactions were reported to be about 3 percent each for positional headaches, hypotension and backache; 2 percent for shivering; and less than 1 percent each for peripheral nerve symptoms, nausea, respiratory inadequacy and double vision.  Many of these observations may be related to local anesthetic techniques, with or without a contribution from the local anesthetic.

    In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter may occur.  Subsequent adverse effects may depend partially on the amount of drug administered subdurally.  These may include spinal block of varying magnitude (including total spinal block), hypotension secondary to spinal block, loss of bladder and bowel control, and loss of perineal sensation and sexual function.  Persistent motor, sensory and/or autonomic  (sphincter control) deficit of some lower spinal segments with slow recovery (several months) or incomplete recovery have been reported in rare instances when caudal or lumbar epidural block has been attempted.  Backache and headache have also been noted following use of these
    anesthetic procedures.

    There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration.

    Hematologic

    Methemoglobinemia.

  • OVERDOSAGE

    Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see ADVERSE REACTIONS,  WARNINGS, and PRECAUTIONS).

    Management of Local Anesthetic Emergencies
    The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection.  At the first sign of change, oxygen should be administered.

    The first step in the management of convulsions, as well as underventilation or apnea due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask.  Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously.  Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously.  The clinician should be familiar, prior to the use of local anesthetics, with these anticonvulsant drugs.  Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).

    If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.  Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted.  If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted.

    Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated.

    Dialysis is of negligible value in the treatment of acute overdosage with lidocaine HCl.

    The oral LD50 of lidocaine HCl in non-fasted female rats is 459 (346 to 773) mg/kg (as the salt) and 214 (159 to 324) mg/kg (as the salt) in fasted female rats.

  • DOSAGE AND ADMINISTRATION

    Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Xylocaine Injection for various types of anesthetic procedures.  The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions.  When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated.

    There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Xylocaine is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).

    These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures.  The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient.  In all cases the lowest concentration and smallest dose that will produce the desired result should be given.  Dosages should be reduced for children and for the elderly and debilitated patients and patients with cardiac and/or liver disease.

    The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used.  Thus, an increase in volume and concentration of Xylocaine Injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia.  However, increasing the volume and concentration of Xylocaine Injection may result in a more profound fall in blood pressure when used in epidural anesthesia. Although the incidence of side effects with lidocaine HCl is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly
    proportional to the total dose of local anesthetic agent injected.

    For intravenous regional anesthesia, only the 50 mL single dose vial containing Xylocaine (lidocaine HCl) 0.5% Injection should be used.

    Epidural Anesthesia
    For epidural anesthesia, only the following dosage forms Xylocaine Injection are recommended:

    1% without epinephrine 10 mL Plastic Ampule 
    1% without epinephrine 30 mL single dose solutions 
    1% with epinephrine   1:200,000 30 mL single dose solutions 
    1.5% without epinephrine 10 mL Plastic Ampule 
    1.5% without epinephrine 20 mL Plastic Ampule 
    1.5% with epinephrine  1:200,000 30 mL ampules, 30 mL single dose solutions 
    2% without epinephrine 10 mL Plastic Ampule 
    2% with epinephrine   1:200,000 20 mL ampules, 20 mL single dose solutions 

    Although these solutions are intended specifically for epidural anesthesia, they may also be used for infiltration and peripheral nerve block, provided they are employed as single dose units.  These solutions contain no bacteriostatic agent.

    In epidural anesthesia, the dosage varies with the numb  r of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome).

    Caudal and Lumbar Epidural Block
    As a precaution against the adverse experience sometimes observed following unintentional penetration of the subarachnoid space, a test dose such as 2 to 3 mL of 1.5% lidocaine HCl should be administered at least 5 minutes prior to injecting the total volume required for a lumbar or caudal epidural block.  The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose (10 to 15 mcg have been suggested), may serve as a warning of unintentional intravascular injection.  If injected into a blood vessel, this amount of epinephrine is likely to produce a transient “epinephrine response” within 45 seconds, consisting of an increase in heart rate and systolic blood pressure, circumoral pallor, palpitations and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or
    more seconds.  Patients on beta blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure.  Adequate time should be allowed for onset of anesthesia after administration of each test dose.  The rapid injection of a large volume of Xylocaine Injection through the catheter should be avoided, and, when feasible, fractional doses should be administered.

    In the event of the known injection of a large volume of local anesthetic solution into the subarachnoid space, after suitable resuscitation and if the catheter is in place, consider attempting the recovery of drug by draining a moderate amount of cerebrospinal fluid (such as 10 mL) through the epidural catheter.

    MAXIMUM RECOMMENDED DOSAGES

    Adults
    For normal healthy adults, the individual maximum recommended dose of lidocaine HCl with epinephrine should not exceed 7 mg/kg (3.5 mg/lb) of body weight, and in general it is recommended that the maximum total dose not exceed 500 mg.  When used without epinephrine the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight, and in general it is recommended that the maximum total dose does not exceed 300 mg.  For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes.  When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia.

    The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total.  One half of the total dose is usually administered to each side. Inject slowly, five minutes between sides (see also discussion of paracervical block in PRECAUTIONS).

    For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.

    Children
    It is difficult to recommend a maximum dose of any drug for children, since this varies as a function of age and weight.  For children over 3 years of age who have a normal lean body mass and normal body development, the maximum dose is determined by the child’s age and weight.  For example, in a child of 5 years weighing 50 lbs the dose of lidocaine HCl should not exceed 75 to 100 mg (1.5 to 2 mg/lb). The use of even more dilute solutions (i.e., 0.25 to 0.5%) and total dosages not to exceed 3 mg/kg (1.4 mg/lb) are recommended for induction of intravenous regional anesthesia in children.

    In order to guard against systemic toxicity, the lowest effective concentration and lowest effective dose should be used at all times.  In some cases it will be necessary to dilute available concentrations with 0.9% sodium chloride injection in order to obtain the required final concentration.

    NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit.  The Injection is not to be used if its color is pinkish or darker than slightly yellow or if it contains a precipitate.

    Table 1:  Recommended Dosages

    Procedure 

    Xylocaine (lidocaine hydrochloride)

    Injection (without epinephrine)

    Conc (%)Vol (mL) Total Dose (mg) 
    Infiltration    
       Percutaneous  0.5 or 1 1 to 60 5 to 300
       Intravenous regional  0.5 10 to 60 50 to 300
    Peripheral Nerve Blocks, e.g.,    
       Brachial  1.5 15 to 20 225 to 300
       Dental  2 1 to 5 20 to 100
       Intercostal 1 3 30
       Paravertebral 1 3 to 5 30 to 50
       Pudendal (each side) 1 10 100
    Paracervical    
       Obstetrical analgesia   
       (each side) 1 10 100
    Sympathetic Nerve Blocks, e.g.,    
       Cervical (stellate ganglion) 1 5 50
       Lumbar 1 5 to 10 50 to 100
    Central Neural Blocks    
       Epidural*   
         Thoracic  1 20 to 30 200 to 300
         Lumbar   
         Analgesia 1 25 to 30 250 to 300
         Anesthesia 1.5 15 to 30 225 to 300
      2 10 to 15 200 to 300
    Caudal    
       Obstetrical analgesia 1 20 to 30 200 to 300
       Surgical anesthesia 1.5  15 to 20 225 to 300

    *Dose determined by number of dermatomes to be anesthetized (2 to 3 mL/dermatome).

    THE ABOVE SUGGESTED CONCENTRATIONS AND VOLUMES SERVE ONLY AS A GUIDE.OTHER VOLUMES AND CONCENTRATIONS MAY BE USED PROVIDED THE TOTAL MAXIMUM RECOMMENDED DOSE IS NOT EXCEEDED.

  • STERILIZATION, STORAGE AND TECHNICAL PROCEDURES

    Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc) should not be used for skin or mucous membrane disinfection as they have been related to incidents of swelling and edema.  When chemical disinfection of multi-dose vials is desired, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended.  Many commercially available brands of rubbing alcohol, as well as solutions of ethyl alcohol not of USP grade, contain denaturants which are injurious to rubber and therefore are not to be used.

    Dosage forms listed as Xylocaine-MPF indicate single dose solutions that are Methyl Paraben Free (MPF).

  • HOW SUPPLIED

    Xylocaine® (lidocaine HCl Injection, USP)

    Product Code Unit of Sale Strength Each 
     480457 NDC 63323-484-57
     Unit of 25
     0.5%
     (250 mg per 50 mL)
     (5 mg per mL)
     NDC 63323-484-57
     50 mL Multiple Dose Vial
     480527 NDC 63323-485-27
     Unit of 25
     1%
     (200 mg per 20 mL)
     (10 mg per mL)
     NDC 63323-485-01
     20 mL Multiple Dose Vial
     480557 NDC 63323-485-57
     Unit of 25
     1%
     (500 mg per 50 mL)
     (10 mg per mL)
     NDC 63323-485-03
     50 mL Multiple Dose Vial
     480617 NDC 63323-486-17
     Unit of 25
     2%
     (200 mg per 10 mL)
     (20 mg per mL)
     NDC 63323-486-01
     10 mL Multiple Dose Vial
     480627 NDC 63323-486-27
     Unit of 25
     2%
     (400 mg per 20 mL)
     (20 mg per mL)
     NDC 63323-486-02
     20 mL Multiple Dose Vial
     480657 NDC 63323-486-57
     Unit of 25
     2%
     (1,000 mg per 50 mL)
     (20 mg per mL)
     NDC 63323-486-05
     50 mL Multiple Dose Vial

    Xylocaine® -MPF (lidocaine HCl Injection, USP)

     Product Code Unit of Sale  Strength  Each 
     491157 NDC 63323-491-57
     Unit of 25
     0.5%
     (250 mg per 50 mL)
     (5 mg per mL)
     NDC 63323-491-01
     50 mL Single Dose Vial
     491227 NDC 63323-492-27
     Unit of 25
     1%
     (20 mg per 2 mL)
     (10 mg per mL)
     NDC 63323-492-04
     2 mL Single Dose Vial
     491257 NDC 63323-492-57
     Unit of 25
     1%
     (50 mg per 5 mL)
     (10 mg per mL)
     NDC 63323-492-09
     5 mL Single Dose Vial
     491297 NDC 63323-492-97
     Unit of 5
     1%
     (100 mg per 10 mL)
     (10 mg per mL)
     NDC 63323-492-08
    10 mL Plastic Ampule
     491237 NDC 63323-492-37
     Unit of 25
     1%
     (300 mg per 30 mL)
     (10 mg per mL)
     NDC 63323-492-07
     30 mL Single Dose Vial
     491231 NDC 63323-492-31
     Unit of 5
     1%
     (300 mg per 30 mL)
     (10 mg per mL)
     NDC 63323-492-03
     30 mL Single Dose Vial
     491397 NDC 63323-493-97
     Unit of 5
     1.5%
     (150 mg per 10 mL)
     (15 mg per mL)
     NDC 63323-493-03
    10 mL Plastic Ampule
     491391 NDC 63323-493-91
     Unit of 5
     1.5%
     (300 mg per 20 mL)
     (15 mg per mL)
     NDC 63323-493-01
     20 mL Plastic Ampule
     491527 NDC 63323-495-27
     Unit of 25
     2%
     (40 mg per 2 mL)
     (20 mg per mL)
     NDC 63323-495-09
     2 mL Single Dose Vial
     491507 NDC 63323-495-07
     Unit of 25
     2%
     (100 mg per 5 mL)
     (20 mg per mL)
     NDC 63323-495-04
     5 mL Single Dose Vial
     491697 NDC 63323-496-97
     Unit of 5
     2%
     (200 mg per 10 mL)
     (20 mg per mL)
     NDC 63323-496-03
    10 mL Plastic Ampule

    Xylocaine® (lidocaine HCl and epinephrine Injection, USP) with Epinephrine 1:100,000

    Product Code Unit of Sale  Strength  Each  
     480217 NDC 63323-482-17
     Unit of 25
     1%
     (100 mg per 10 mL)
     (10 mg per mL)
     NDC 63323-482-01
     10 mL Multiple Dose Vial
     480227 NDC 63323-482-27
     Unit of 25
     1%
     (200 mg per 20 mL)
     (10 mg per mL)
     NDC 63323-482-03
     20 mL Multiple Dose Vial
     480257 NDC 63323-482-57
     Unit of 25
     1%
     (500 mg per 50 mL)
     (10 mg per mL)
     NDC 63323-482-05
     50 mL Multiple Dose Vial
     480327 NDC 63323-483-27
     Unit of 25
     2%
     (400 mg per 20 mL)
     (20 mg per mL)
     NDC 63323-483-03
     20 mL Multiple Dose Vial
     480357 NDC 63323-483-57
     Unit of 25
     2%
     (1,000 mg per 50 mL)
     (20 mg per mL)
     NDC 63323-483-01
     50 mL Multiple Dose Vial

    Xylocaine® (lidocaine HCl and epinephrine Injection, USP) with Epinephrine 1:200,000

     Product Code Unit of Sale  Strength Each
     480157 NDC 63323-481-57
     Unit of 25

     0.5%
    (250 mg per 50 mL)
    (5 mg per mL)

     NDC 63323-481-01
     50 mL Multiple Dose Vial

    Xylocaine®-MPF (lidocaine HCl and epinephrine Injection, USP) with Epinephrine 1:200,000

    Product Code  Unit of Sale Strength  Each
     480717 NDC 63323-487-17
     Unit of 25
     1%
     (100 mg per 10 mL)
     (10 mg per mL)
    NDC 63323-487-01
    10 mL Single Dose Vial
     480737 NDC 63323-487-37
     Unit of 25
     1%
     (300 mg per 30 mL)
     (10 mg per mL)
    NDC 63323-487-07
    30 mL Single Dose Vial
     480731 NDC 63323-487-31
     Unit of 5
     1%
     (300 mg per 30 mL)
     (10 mg per mL)
    NDC 63323-487-03
    30 mL Single Dose Vial
     480817 NDC 63323-488-17
     Unit of 25
     1.5%
     (150 mg per 10 mL)
     (15 mg per mL)
    NDC 63323-488-01
    10 mL Single Dose Vial
     480837 NDC 63323-488-37
     Unit of 25
     1.5%
     (450 mg per 30 mL)
     (15 mg per mL)
    NDC 63323-488-07
    30 mL Single Dose Vial
     480831 NDC 63323-488-31
     Unit of 5
     1.5%
     (450 mg per 30 mL)
     (15 mg per mL)
    NDC 63323-488-03
    30 mL Single Dose Vial
     480917 NDC 63323-489-17
     Unit of 25
     2%
     (200 mg per 10 mL)
     (20 mg per mL)
    NDC 63323-489-01
    10 mL Single Dose Vial
     480927 NDC 63323-489-27
     Unit of 25
     2%
     (400 mg per 20 mL)
     (20 mg per mL)
    NDC 63323-489-02
    20 mL Single Dose Vial
     480921 NDC 63323-489-21
     Unit of 5
     2%
     (400 mg per 20 mL)
     (20 mg per mL)
    NDC 63323-489-03
    20 mL Single Dose Vial

    For single-dose vials and ampules: Discard unused portion.

    All solutions should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

    Protect from light.

    All trademarks are the property of Fresenius Kabi USA, LLC.

    Fresenius Kabi Logo

    Fresenius Kabi Logo

    www.fresenius-kabi.com/us

    4 5 1 1 7 5 F
    Revised: March 2019

  • SODIUM CHLORIDE - sodium chloride injection

    Sodium Chloride Injection, USP

    0.9%

    Fresenius Kabi USA, LLC

  • DESCRIPTION

    Sodium Chloride Injection, USP, 0.9% is a sterile, nonpyrogenic solution.  The osmolarity is 300 mOsmol per liter (calculated).

    Each mL contains:  Sodium chloride 9 mg; Water for Injection q.s.  It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single dose containers.  Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (pH 4.5-7.0).

    Sodium chloride occurs as colorless cubic crystals or white crystalline powder and has a saline taste. Sodium chloride is freely soluble in water.  It is soluble in glycerin and slightly soluble in alcohol.

    The empirical formula for sodium chloride is NaCl and the molecular weight is 58.44.

  • CLINICAL PHARMACOLOGY

    Sodium chloride in water dissociates to provide sodium (Na +) and chloride (Cl —) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance.

    The distribution and excretion of sodium (Na +) and chloride (Cl —) are largely under the control of the kidney which maintains a balance between intake and output.

    The small volume of fluid and amount of sodium chloride provided by Sodium Chloride Injection, USP, 0.9%, when used only as a vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in very small infants.

    Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1 to 1.5 liters each for insensible water loss by perspiration and urine production).

    Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na +) plays a major role in maintaining physiologic equilibrium.

  • INDICATIONS AND USAGE

    Sodium Chloride Injection, USP, 0.9% preparations are indicated for diluting or dissolving drugs for intramuscular, intravenous or subcutaneous injection according to instructions of the manufacturer of the drug to be administered.

    Sodium Chloride Injection, USP, 0.9% is also indicated for use in flushing of intravenous catheters.

  • WARNINGS

    For use in newborns, when a sodium chloride solution is required for preparation or diluting medications or in flushing intravenous catheters, only preservative free Sodium Chloride Injection, USP, 0.9% should be used. 


  • PRECAUTIONS

    General
    Consult the manufacturer’s instructions for choice of vehicle, appropriate dilution or volume for dissolving the drugs to be injected, including the route and rate of injection. Inspect reconstituted (diluted or dissolved) drugs for clarify (if soluble) and freedom from unexpected precipitation or discoloration prior to administration.

    Pregnancy
    Pregnancy Category C—Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP, 0.9%. It is also not known whether Sodium Chloride Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection, USP, 0.9% should be given to a pregnant woman only if clearly needed.

  • ADVERSE REACTIONS

    Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.

    If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures and, if possible, retrieve and save the remainder of the unused vehicle for examination.

  • OVERDOSAGE

    When used as a diluent, solvent or intravascular flushing solution, this parenteral preparation is unlikely to pose a threat of sodium chloride or fluid overload except possibly in very small infants. In the event these should occur, reevaluate the patient and institute appropriate corrective measures.  (See
    PRECAUTIONS  and ADVERSE REACTIONS). 


  • DOSAGE AND ADMINISTRATION

    Before Sodium Chloride Injection, USP, 0.9% is used as a vehicle for the administration of a drug, specific references should be checked for any possible incompatibility with sodium chloride.

    The volume of the preparation to be used for diluting or dissolving any drug for injection is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacturer.

    Sodium Chloride Injection, USP, 0.9% is also indicated for use in flushing intravenous catheters.  Prior to and after administration of the medication, the intravenous catheter should be flushed in its entirety with Sodium Chloride Injection, USP, 0.9%.  Use in accord with any warnings or precautions appropriate to the medication being administered.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  • HOW SUPPLIED

    Sodium Chloride Injection, USP, 0.9%, preservative free, is available as follows: 

    Product CodeUnit of Sale Strength Each 
    918602 63323-186-02
    Trays of 25
     
    0.9% (18 mg per 2 mL)
    (9 mg per mL)
     
    NDC 63323-186-04
    2 mL fill, in a 3 mL Single-Dose vial
    918610 63323-186-10
    Trays of 25
     
    0.9% (90 mg per 10 mL)
    (9 mg per mL)
     
    NDC 63323-186-01
    10 mL Single-Dose vial
    918620 63323-186-20
    Trays of 25
     
    0.9% (180 mg per 20 mL)
    (9 mg per mL)
     
    NDC 63323-186-03
    20 mL Single-Dose vial

    Preservative Free. Discard unused portion.

    Use only if solution is clear and seal intact.

    Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].

    Fresenius Kabi Logo

    Fresenius Kabi Logo


    www.fresenius-kabi.com/us

    45764E

    Revised: October 2018

  • POVIDONE-IODINE

    APLICARE POVIDONE-IODINE TRIPLES- povidone-iodine solution

    Aplicare Products, LLC

    Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

  • ACTIVE INGREDIENT

    Povidone-iodine USP

  • PURPOSE

    Antiseptic

  • USE

    Antiseptic skin preparation

  • WARNINGS

    Do not use

    • if allergic to iodine
    • in the eyes

    For external use only

    Avoid pooling beneath patient

    Avoid excessive heat. Store at room temperature.

    Ask a doctor before use if injuries are

    • deep or puncture wounds
    • serious burns

    Stop use and ask a doctor if

    • redness, irritation, swelling or pain persists or increases
    • infection occurs


    Keep out of reach of children.

     In case of accidental ingestion, seek professional assistance or consult a poison control center immediately.

  • DIRECTIONS

    Apply locally as needed

  • INACTIVE INGREDIENTS

    • citric acid,
    • disodium phosphate,
    • nonoxynol-9,
    • sodium hydroxide,
    • water
  • OTHER INFORMATION

    • 1% titratable iodine
    • Not made with natural rubber latex
    • For hospital or professional use only

    Applicator is STERILE if package is intact.

    Manufactured by:

    Aplicare Products, LLC,

    550 Research Parkway,

    Meriden, CT 06450 USA

    Made in USA

    For questions or comments
    800-633-5463

    Revised: 12/2019

  • ALCOHOL PREP PAD

    ALCOHOL PREP- isopropyl alcohol swab

    Dynarex Corporation

    Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

  • ACTIVE INGREDIENT

    Isopropyl Alcohol 70 % v/v

  • PURPOSE

    Antiseptic

  • USE

    For preparation of the skin prior to injection.

  • WARNINGS

    • For external use only
    • Flammable, keep away from flame or fire
    • Not for use with electrocautionary devices or procedures
    • Do not use in eyes
    • Sterile unless package is damaged or open

    Stop use and ask a doctor if:

    • Irritation or redness develops
    • Condition persists for more than 72 hours
    • Cleansing of an injection site

    Keep out of reach of children.

    In case of accidental ingestion, seek professional assistance or consult a poison control center immediately.


  • DIRECTIONS

    • Wipe injection site vigorously and discard

  • INACTIVE INGREDIENT

    • water
  • OTHER INFORMATION

    • Store at room temperature: 15 deg C to 30 deg C   59 deg F to 86 deg F
    • avoid excessive heat

    Reorder No. 1113

    Made in China

    Manufactured for:

    Dynarex Corporation

    Orangeburg, NY 10962

    www.dynarex.com

    Revised: 11/2019

  • PRINCIPAL DISPLAY PANEL: P-Care 100MX

    NDC 49836-000-19

    RX-Only

    P-Care 100MX

    Kit Contains:

    1 MARCAINE† 0.5% Single Dose Vial (5 mg/mL) (10 mL)
    1 XYLOCAINE†- MPF 1% Single Dose Vial (10 mg/mL) (5mL)
    1 Sodium Chloride Injection, USP 0.9% Single Dose Vial (10 mL)
    1 Sterile Povidone-Iodine Swabsticks (3 Swabs)
    1 Sterile Pair Nitrile Powder-Free Gloves (Size 7.5)
    1 Sterile Towel Drape
    1 Sterile Fenestrated Towel Drape
    2 Sterile Adhesive Bandage
    2 Sterile Adhesive Spot Bandage
    3 Sterile Packs of 4x4 Gauze (6 Gauzes)
    5 Sterile Isopropyl Alcohol 70% Prep Pad

    Needles and Syringes Not Included

    1 Dose

     1 ONE NEEDLE,
        ONE SYRINGE,
        ONLY ONE TIME.
    Safe Injection Practices Coalition
    www.ONEandONLYcampaign.org

    Members of One & Only Campaign

    P-Care 100MX

    DISTRIBUTED BY:
    SCHMIGS
    HAUPPAUGE, NY 11788
    NDC 49836-000-19

    MANUFACTURED BY:
    Rx Pharma Pack
    HAUPPAUGE, NY 11788

    Questions/Comments 1-844-632-7898

    Kit Contents:

    MARCAINE  0.5% (5 mg/mL)* (Hospira, Inc.)
    Bupivacaine HCl Injection, USP

    XYLOCAINE- MPF 1% (10 mg/mL)* (APP Fresenius Kabi USA, LLC)
    Lidocaine HCl Injection, USP

    Sodium Chloride Injection, USP 0.9% (10 mL)* (APP Pharmaceuticals, LLC)

    Sterile APLICARE Povidone-lodine Swabsticks* (Clorox Professional Products Company)

    Sterile Nitrile Powder-Free Gloves* (Dynarex) - Size 7.5

    Sterile Towel Drape* (Dynarex)

    Sterile Fenestrated Towel Drape* (Dynarex)

    Sterile Adhesive Bandage* (Dynarex)

    Sterile Adhesive Spot Bandage* (Dynarex)

    Sterile 4x4 Gauze* (Dynarex)

    Sterile Alcohol Prep Pad 70% by Volume* (Dynarex)

    †All trademarks and registered trademarks noted herein are the property of their respective owners.
    *Internal package components remain sterile when stated as long as items are unopened and undamaged.

    WARNING: KEEP THIS AND ALL MEDICATION
    OUT OF THE REACH OF CHILDREN. IN CASE OF
    ACCIDENTAL OVERDOSE, SEEK PROFESSIONAL
    ASSISTANCE OR CONTACT A POISON CONTROL
    CENTER IMMEDIATELY.

    PROTECT FROM LIGHT I AVOID FREEZING

    STORE AT CONTROLLED ROOM TEMPERATURE
    20º-25ºC (68º-77º F) [SEE USP CONTROLLED
    ROOM TEMPERATURE]

    DO NOT REFRIGERATE.

    For Single use Only.

    Directions for Use: See enclosed inserts.

    SUSTAINABLE        Certified Sourcing
    FORESTRY             www.sfiprogram.org
    INITIATIVE               SFI-01376

    ORG 04/2017

    This product is not eligible for Medicare or Medicaid reimbursement.

    P-CARE 100MX

    P-CARE 100MX

  • INGREDIENTS AND APPEARANCE
    P-CARE 100MX 
    bupivacaine hydrochloride, lidocaine hydrochloride, sodium chloride, povidone-iodine, isopropyl alcohol kit
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:49836-000
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:49836-000-191 in 1 PACKAGE, COMBINATION; Type 1: Convenience Kit of Co-Package06/16/2017
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL, SINGLE-DOSE 10 mL
    Part 21 VIAL, SINGLE-DOSE 5 mL
    Part 31 VIAL, SINGLE-DOSE 10 mL
    Part 41 PACKET 6.5 mL
    Part 55 POUCH 2.75 mL
    Part 1 of 5
    MARCAINE 
    bupivacaine hydrochloride injection, solution
    Product Information
    Route of AdministrationEPIDURAL, INTRACAUDAL, PERINEURAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BUPIVACAINE HYDROCHLORIDE (UNII: 7TQO7W3VT8) (BUPIVACAINE - UNII:Y8335394RO) BUPIVACAINE HYDROCHLORIDE ANHYDROUS5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    110 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01696408/16/2005
    Part 2 of 5
    XYLOCAINE MPF 
    lidocaine hydrochloride injection, solution
    Product Information
    Route of AdministrationEPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LIDOCAINE HYDROCHLORIDE ANHYDROUS (UNII: EC2CNF7XFP) (LIDOCAINE - UNII:98PI200987) LIDOCAINE HYDROCHLORIDE ANHYDROUS10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 7 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    15 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA00648808/12/2010
    Part 3 of 5
    SODIUM CHLORIDE 
    sodium chloride injection
    Product Information
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698) SODIUM CHLORIDE9 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    110 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA08891208/10/2000
    Part 4 of 5
    APLICARE POVIDONE-IODINE TRIPLES 
    povidone-iodine solution
    Product Information
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    POVIDONE-IODINE (UNII: 85H0HZU99M) (IODINE - UNII:9679TC07X4) IODINE10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)  
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    NONOXYNOL-9 (UNII: 48Q180SH9T)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    16.5 mL in 1 PACKET; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    OTC MONOGRAPH NOT FINALpart333A03/01/1998
    Part 5 of 5
    STERILE ALCOHOL PREP PADS 
    isopropyl alcohol swab
    Product Information
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ISOPROPYL ALCOHOL (UNII: ND2M416302) (ISOPROPYL ALCOHOL - UNII:ND2M416302) ISOPROPYL ALCOHOL0.7 mL  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    10.55 mL in 1 POUCH; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    OTC MONOGRAPH NOT FINALpart333A07/01/2010
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01696406/16/2017
    Labeler - RX PHARMA-PACK, INC. (962149634)
    Establishment
    NameAddressID/FEIBusiness Operations
    RX PHARMA-PACK, INC.962149634PACK(49836-000)